KNSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KNSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Kiniksa Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2024 was $-70.8 Mil. Kiniksa Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $418.2 Mil. Therefore, Kiniksa Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -16.93%.
The historical rank and industry rank for Kiniksa Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
During the past 8 years, Kiniksa Pharmaceuticals's highest Return-on-Tangible-Equity was 67.45%. The lowest was -108.91%. And the median was -62.11%.
The historical data trend for Kiniksa Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -64.15 | -60.06 | -66.12 | 67.45 | 3.52 |
Kiniksa Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -13.09 | 15.64 | -14.18 | 24.95 | -16.93 |
For the Biotechnology subindustry, Kiniksa Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kiniksa Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals's Return-on-Tangible-Equity falls into.
Kiniksa Pharmaceuticals's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | 14.084 | / | ( (377.899 | + | 421.589 ) | / 2 ) | |
= | 14.084 | / | 399.744 | ||||
= | 3.52 % |
Kiniksa Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -70.816 | / | ( (421.589 | + | 414.895) | / 2 ) | |
= | -70.816 | / | 418.242 | ||||
= | -16.93 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
Kiniksa Pharmaceuticals (NAS:KNSA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael R Megna | officer: Chief Accounting Officer | 1050 HINGHAM STREET, ROCKLAND MA 02370 |
John Paolini | officer: Chief Medical Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Barry D Quart | director | C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549 |
Felix Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Brothers Life Sciences Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors (gp) Llc | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | director | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Eben Tessari | officer: Chief Business Officer | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Arian Pano | officer: Chief Clinical Dev. Officer | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Ross Moat | officer: Group VP & Rilonacept GM | C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Sanj K Patel | director, 10 percent owner, officer: Chairman & CEO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Thomas W. Beetham | 10 percent owner, officer: Chief Legal Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Mark Ragosa | officer: Interim CFO | C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By PurpleRose PurpleRose • 08-02-2022
By Value_Insider Value_Insider • 11-23-2022
By PurpleRose PurpleRose • 08-03-2022
By sperokesalga sperokesalga • 05-02-2023
By GuruFocusNews GuruFocusNews • 02-18-2022
By GuruFocusNews GuruFocusNews • 05-03-2022
By GuruFocusNews GuruFocusNews • 01-10-2022
By sperokesalga sperokesalga • 02-27-2023
By Stock market mentor Stock market mentor • 01-03-2023
By Marketwired • 07-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.